Mölndal, Sweden — December 15, 2025 — Amferia, a Swedish medtech company developing next-generation antimicrobial wound-care solutions, today announced the close of an oversubscribed €3.5 million investment round.
The new funding—led by both existing shareholders and several new investors prominent in global wound care—will accelerate clinical development in human health, scale Amferia’s growing animal-health business, and support commercialization of new products based on its proprietary antimicrobial peptide (AMP) hydrogel platform.
This investment follows a milestone year in which Amferia introduced Europe’s first veterinary wound dressing using antimicrobial peptides, launched in collaboration with leading animal-health partners, and advanced its U.S. regulatory pathway for human wound care.
Fueling Growth Across Human and Veterinary Medicine
According to Amferia CEO and co-founder Anand Rajasekharan, the new financing will help the company advance clinical development toward CE marking and FDA clearance for human health applications in Europe and the United States, as well as expand Amferia’s animal-health footprint in Europe, where the company has already secured commercial agreements with Orkla Wound Care AB and Biokema SA.
“This funding will allow us to continue battling antibiotic-resistant bacteria and speed wound recovery in both human and animal patients,” Rajasekharan said.
“Amferia aims to broaden the new tools we offer clinicians to fight infection and reduce unnecessary antibiotic use. We hope to scale manufacturing and commercialization of our anti-microbial wound-care solution pipeline and broaden the platform to include applications such as surgical materials, implant sterilization, and deep-wound sprays.”
The Race to Solve Global Antimicrobial Resistance
Antimicrobial resistance (AMR) is accelerating at a pace that threatens to become one of the leading causes of human mortality worldwide in coming decades. At least five million people are currently affected by infections caused by antibiotic resistance. In countries with a high incidence of resistant bacteria, a small wound can cause life-threatening infection that can’t be treated with traditional antibiotics.
Antimicrobial peptides are known for their ability to kill bacteria due to their positive electrostatic charge, which attracts the negatively charged infectious bacteria. This allows peptides to puncture bacterial membranes and destroy the cells. However, their fragility in biological environments has been a major challenge to developing peptides as a viable treatment—naturally occurring enzymes in the body can destroy them within seconds.
Amferia’s management team – My Nyblom, Saba Atefyekta, Edvin Blomstrand, Rojan Modaresi, Daniel Hagberg, and Anand Rajasekharan, Photo: Saba Atefyekta
(Not Pictured above: Maya Awada, Peter Andersson, Therese Rydell, Ingvar Karlsson, Ulrika Holmquist).
Amferia’s breakthrough is the development of a hydrogel platform, encasing the peptides in a solid protective gel. This design shields the vulnerable facets of peptides while allowing their bacteria-killing structures to remain exposed—and lethal to even antibiotic-resistant bacteria. Amferia’s antimicrobial hydrogel kills bacteria without harming surrounding body tissue.
“The hydrogel technology we’ve developed enables the safe and stable use of antimicrobial peptides—one of nature’s most powerful defenses—while preventing the enzyme degradation that has historically limited their use,” Rajasekharan said.
Research shows that combining Amferia’s hydrogel with antibiotics can dramatically amplify their bactericidal effect—up to 64 times stronger—demonstrating its potential to reshape infection management.
A Platform for Multiple New Product Lines
The capital infusion allows Amferia to continue to develop products applying the peptide-hydrogel technology across a broad range of clinical and veterinary use cases, including:
Dry-to-low exuding wound dressings
Post-operative and chronic wound care
Trauma and burn applications
Surgical materials
Antimicrobial coatings for implants and medical devices
The company continues to expand its veterinary presence in Europe with the BactiDefend™ dressing and is advancing human-health pipeline products built on the same underlying platform.
Looking Ahead
Amferia continues to expand its product pipeline, invest in research, and collaborate with global partners to redefine how infections are prevented and managed. By stabilizing one of nature’s most effective bacterial defenses, the company offers a transformative platform with the potential to strengthen antibiotic treatments and improve outcomes across healthcare.
Learn more about Amferia
Media Contact
Anand Rajasekharan
CEO & Co-Founder, Amferia
+46 76 298 12 38
anandk@amferia.com